Economic burden of cancer across the European Union: a population-based cost analysis.
about
Cancer registries in Europe-going forward is the only optionCancer Metabolism and Drug ResistanceAnalysis and valuation of the health and climate change cobenefits of dietary changeA Review on Cost-Effectiveness and Cost-Utility of Psychosocial Care in Cancer PatientsPatients' Preferences for Outcome, Process and Cost Attributes in Cancer Treatment: A Systematic Review of Discrete Choice Experiments.Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020.The economic burden of dementia in China, 1990-2030: implications for health policy.French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends.Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer.Investments in cancer research awarded to UK institutions and the global burden of cancer 2000-2013: a systematic analysis.Cost of care for cancer patients in England: evidence from population-based patient-level data.Costs of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysisImproving selection criteria for lung cancer screening. The potential role of emphysema.Trends and Patterns of Disparities in Oral Cavity and Pharyngeal Cancer in Serbia: Prevalence and Economic Consequences in a Transitional CountryExpenditure of hospital care on cancer in China, from 2011 to 2015.Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls.Beyond treatment - Psychosocial and behavioural issues in cancer survivorship research and practiceLabour productivity losses caused by premature death associated with hepatitis C in Spain.The patient-breast cancer care pathway: how could it be optimized?Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative MedicineThe Economic Burden of Cancers Attributable to Metabolic Syndrome in KoreaCost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.Is England closing the international gap in cancer survival?Cost-utility analyses of drug therapies in breast cancer: a systematic review.Projecting productivity losses for cancer-related mortality 2011 - 2030.Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk.Increasing Receipt of High-Tech/High-Cost Imaging and Its Determinants in the Last Month of Taiwanese Patients With Metastatic Cancer, 2001-2010: A Retrospective Cohort Study.The Productivity Costs of Premature Mortality Due to Cancer in Australia: Evidence from a Microsimulation Model.Costs of breast cancer care in Mexico: analysis of two insurance coverage scenariosCost of breast cancer based on real-world data: a cancer registry study in ItalyCost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review.Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study.Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.Estimating the cost of caring for people with cancer at the end of life: A modelling study.Long-term Realism and Cost-effectiveness: Primary Prevention in Combatting Cancer and Associated Inequalities Worldwide.Advanced therapy medicinal products: current and future perspectivesChallenges in generating costs and utilisation rates associated with castration-resistant prostate cancerThe Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer
P2860
Q26746893-AD2B3007-4EBB-4E61-8F40-A3D61B49E1F8Q26782042-42A5B591-8204-4E5F-9309-0C86E288BBEFQ28005515-683962DF-79C2-4C4C-A32C-9EAE463972C7Q28079810-4BD32049-CAF7-4E0D-B95A-AEA03525BA90Q30235008-5ADAA3F2-5F78-4928-9645-7C68F4C7DE98Q30378272-2CA75DE4-ABC3-4738-A5D8-D7E68904C317Q30379575-852F7B09-0940-4AC1-9D5C-B63975063175Q30384043-50AE8500-D266-4949-89D4-9AEA129AE61EQ30490454-97B32298-2EB8-48A2-8B2F-2A8EE77FF121Q30491468-7838EF56-347A-465D-9A2F-819EA2B68517Q31075231-B8DA1D40-BE64-4B27-9265-CCD0A49A370DQ31143305-A332A438-7F7D-4BDF-8C4C-BCA1F88FFCE7Q33735712-A1FE1E87-9FA9-4EEC-85EA-F074026542D8Q33804329-85BF02DC-FA6E-440A-8F83-D8D5BB30E54DQ33871912-E52C467F-6BA9-4F07-83FD-B4F5E71F9E66Q34450266-F8DD0E8A-6522-4CEB-A243-3A50636A795EQ34604445-75256B23-5A1A-4A2A-A63D-4AC8E35A9204Q35558268-5EC645CF-E94E-4CCC-B9DD-BCB208EBE42CQ35604139-EFA7E1A2-9DA2-49A3-B011-362C0BDE1E5AQ35611160-71A1F94F-50B4-4651-81D9-D48CD1E108E0Q35928383-E01D0416-9F50-4261-A821-CB6FD0C98364Q35973377-63DBC0C5-0BD2-4719-BD93-D4537FD8EC99Q36001592-6BF355F5-1D3E-47F7-BDD0-C76DF976D663Q36027055-C3AB0C75-8ABE-4FE1-8654-1369FFA4A7CCQ36116276-5B3A3CD3-94A0-4A0B-A5FC-724A6E12D9E2Q36166785-EDD461ED-14B3-4B59-A371-FA28C2CB49EDQ36192713-D1AABA0E-EB95-42C1-AB7F-EA593F0A1150Q36195119-CE92277D-B377-4474-82CA-7164B01F7C58Q36220159-9472EBB2-29EE-4659-BD7F-5AE75F9E7EB8Q36244576-F053096E-D6BD-4B44-815E-78055CFB1BFBQ36260314-B71F35D6-426C-4F53-A42B-BBCA55638108Q36276324-45F1826F-BE59-4EC2-888C-3F0AFC8DD29CQ36280255-5E10210A-66F4-427E-A128-C591471FD5F8Q36307517-E5A72B8A-9570-4EC0-81C0-976ECAC0AE97Q36345168-07912BDD-6EAC-41DC-B85F-4C8F645E318DQ36356696-4AFD8E52-B03D-4876-9BFF-B0D225380806Q36840842-59D9DD90-CDDF-4CBC-ADFF-5CC34C5D6F92Q36897614-A29C0F68-776C-4933-A19B-7C168DCABE4DQ37016576-1A4CEA56-77BF-4947-B167-744913C7EF14Q37124737-2F62B105-C4A5-470D-9047-0C46B5854FF9
P2860
Economic burden of cancer across the European Union: a population-based cost analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Economic burden of cancer across the European Union: a population-based cost analysis.
@en
Economic burden of cancer across the European Union: a population-based cost analysis.
@nl
type
label
Economic burden of cancer across the European Union: a population-based cost analysis.
@en
Economic burden of cancer across the European Union: a population-based cost analysis.
@nl
prefLabel
Economic burden of cancer across the European Union: a population-based cost analysis.
@en
Economic burden of cancer across the European Union: a population-based cost analysis.
@nl
P1433
P1476
Economic burden of cancer across the European Union: a population-based cost analysis.
@en
P2093
Ramon Luengo-Fernandez
P304
P356
10.1016/S1470-2045(13)70442-X
P577
2013-10-14T00:00:00Z